CTAD Group Meetings

Join Us At CTAD 2025

December 3, Guidepoint Insights will be hosting a series of group meetings featuring KOLs who will dive deeper into CTAD 2025 updates.

    Wednesday, December 3
    12:00 PM ET - Frank Tarazi
    • TfR brain shuttles, GLP-1s, Biomarkers, Anti-amyloid, Anti-tau, Psychiatry | Medical Director, Neurobehavioral Associates Inc.
    1:00 PM ET - Michael Rafii
    • Down syndrome, Anti-amyloid, pre-symptomatic Alzheimer’s, TfR brain shuttles, GLP-1s | Professor of Clinical Neurology, Keck School of Medicine of USC
    2:00 PM ET - Ronald Schwartz
    • Biomarkers, TfR brain shuttles, GLP-1s, Anti-tau, Neuroinflammation, Anti-amyloid, Psychiatry | Principal Investigator, Hattiesburg Clinic PA
    3:00 PM ET - Jeffrey Apter
    • Clinical trial design, Biomarkers, Anti-amyloid, TfR brain shuttles, GLP-1s, Anti-tau | Senior Attending Physician, Princeton University
    5:00 PM ET - Kristian Steen Frederiksen
    • GLP-1s, EU Anti-amyloid Use, Biomarkers, TfR Brain shuttles | Neurologist of the Memory Disorders Clinic at the Dept. Of Neurology, Rigshospitalet at Denmark
    6:00 PM ET - Samuel Dickson
    • Clinical trial design, Pre-symptomatic Alzheimer’s, Anti-amyloid | Senior VP of Statistics, Pentara Corporation

    *CTAD Group Meetings will be 50 minutes long and available only to attendees. Group meetings are not recorded and transcripts will not be available following the event.